Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes.
Sitamaquine (WR6026), an 8-aminoquinoline derivative, is a new antileishmanial oral drug. As a lipophilic weak base, it rapidly accumulates in acidic compartments, represented mainly by acidocalcisomes. In this work, we show that the antileishmanial action of sitamaquine is unrelated to its level of accumulation in these acidic vesicles. We have observed significant differences in sitamaquine sensitivity and accumulation between Leishmania species and strains, and interestingly, there is no correlation between them. However, there is a relationship between the levels of accumulation of sitamaquine and acidotropic probes, acidocalcisomes size, and polyphosphate levels. The Leishmania major AP3delta-null mutant line, in which acidocalcisomes are devoid of their usual polyphosphate and proton content, is unable to accumulate sitamaquine; however, both the parental strain and the AP3delta-null mutants showed similar sensitivities to sitamaquine. Our findings provide clear evidence that the antileishmanial action of sitamaquine is unrelated to its accumulation in acidocalcisomes.
López-Martín
Carmen
C
Instituto de Parasitología y Biomedicina López-Neyra, CSIC, Parque Tecnológico de Ciencias de la Salud, Armilla, Granada, Spain.
Pérez-Victoria
José María
JM
Carvalho
Luis
L
Castanys
Santiago
S
Gamarro
Francisco
F
D000634:Aminoquinolines / Q000493:pharmacokinetics* / Q000494:pharmacology*; D000818:Animals; D000981:Antiprotozoal Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D022162:Cytoplasmic Vesicles / Q000378:metabolism; D004351:Drug Resistance / Q000235:genetics; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007891:Leishmania / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism*; D007896:Leishmaniasis / Q000188:drug therapy / Q000469:parasitology; D009154:Mutation; D011122:Polyphosphates / Q000378:metabolism; D013045:Species Specificity
D000634:Aminoquinolines; D000981:Antiprotozoal Agents; D011122:Polyphosphates; C080436:8-aminoquinoline
Trends Parasitol. 2007 Jul;23(7):332-9
17493873
Antimicrob Agents Chemother. 2002 Mar;46(3):787-96
11850263
Int J Antimicrob Agents. 2003 Oct;22(4):380-7
14522101
Biochim Biophys Acta. 2007 Feb;1768(2):246-52
16945323
Antimicrob Agents Chemother. 2003 Aug;47(8):2397-403
12878496
Biochemistry. 2006 Oct 17;45(41):12411-23
17029397
Nat Rev Microbiol. 2005 Mar;3(3):251-61
15738951
J Fluoresc. 2008 Sep;18(5):859-66
18210191
Eur J Biochem. 2001 Nov;268(22):5851-6
11722572
Curr Opin Investig Drugs. 2002 Oct;3(10):1446-52
12431016
Antimicrob Agents Chemother. 2007 Aug;51(8):2801-10
17517831
Chem Biol. 1999 Jul;6(7):411-8
10381401
Antimicrob Agents Chemother. 2008 Mar;52(3):875-82
18086841
Mol Biochem Parasitol. 2002 Feb;119(2):225-36
11814574
Am J Trop Med Hyg. 1978 Jul;27(4):751-7
686239
Mol Biol Cell. 2001 Aug;12(8):2364-77
11514622
Parasitol Int. 2000 Jan;48(3):265-9
11227767
J Pharm Pharmacol. 2006 Aug;58(8):1043-54
16872550
Exp Parasitol. 2008 Jun;119(2):308-12
18406406
J Cell Sci. 2008 Mar 1;121(Pt 5):561-70
18252798
Curr Drug Targets Infect Disord. 2001 May;1(1):51-61
12455233
Biochem Biophys Res Commun. 2003 Jun 20;306(1):250-5
12788096
Parasitol Today. 1999 Nov;15(11):443-8
10511686
Int J Antimicrob Agents. 2007 Sep;30(3):229-35
17628445
Adv Parasitol. 2006;61:223-74
16735166
FEBS Lett. 2000 May 12;473(2):203-6
10812075
Mol Biochem Parasitol. 1996 Sep;80(1):15-25
8885219